Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

Group 1 - Eledon Pharmaceuticals will host an R&D Day in New York City on July 9, 2025, focusing on its lead investigational candidate, tegoprubart, and its clinical development in organ and cell transplantation [1] - The event will include discussions on unmet needs in solid organ transplantation, the evolution of clinical endpoints, and strategic opportunities in islet cell transplantation and xenotransplantation [1] - A live Q&A session will feature Eledon's management team and invited key opinion leaders [1] Group 2 - Eledon Pharmaceuticals is a clinical stage biotechnology company developing immune-modulating therapies for life-threatening conditions, with tegoprubart as its lead investigational product [3] - Tegoprubart is an anti-CD40L antibody targeting CD40 Ligand, which plays a central role in immune cell activation, making it a promising target for immunomodulatory therapies [3] - The company is conducting preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS) [3]